Skip to content

13F-HR filed by Commodore Capital LP

Commodore Capital LP filed this 13F-HR for the quarter ended 2022-09-30, filed 2022-11-14, with 30 holding rows worth $621,886,000.

Accession
0001831942-22-000007
Filed
2022-11-14
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q3 2022

A holdings report, 30 entries on the cover page, a total value of $621,886,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $621,886,000 with VALUE read as thousands by filing date, 13F file number 028-20976. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
COGENT BIOSCIENCES INC19240Q201COM4,319,940$64,454,000thousands by filing date
XENON PHARMACEUTICALS INC COM98420N105Stock1,594,932$57,577,000thousands by filing date
VIRIDIAN THERAPEUTICS INC92790C104COM2,696,340$55,302,000thousands by filing date
BELLUS HEALTH INC NEW07987C204COM5,128,557$54,158,000thousands by filing date
MERUS N VN5749R100COM2,615,762$52,394,000thousands by filing date
CYTOKINETICS INC23282W605COM NEW893,646$43,297,000thousands by filing date
ACLARIS THERAPEUTICS INC COM00461U105Stock2,410,622$37,943,000thousands by filing date
AKERO THERAPEUTICS INC00973Y108COM743,472$25,315,000thousands by filing date
SATSUMA PHARMACEUTICALS INC80405P107COM3,711,286$22,268,000thousands by filing date
TRICIDA INC89610F101COM1,975,403$20,702,000thousands by filing date
CYMABAY THERAPEUTICS INC23257D103COM5,738,500$20,085,000thousands by filing date
THIRD HARMONIC BIO INC88427A107COM1,018,569$19,322,000thousands by filing date
SYNDAX PHARMACEUTICALS INC87164F105COM738,110$17,737,000thousands by filing date
CELLDEX THERAPEUTICS INC NEW15117B202COM NEW538,812$15,146,000thousands by filing date
Day One Biopharmaceuticals Inc23954D109Common Stock739,661$14,815,000thousands by filing date
ARROWHEAD PHARMACEUTICALS IN04280A100COM404,078$13,355,000thousands by filing date
KURA ONCOLOGY INC COM50127T109Stock899,407$12,286,000thousands by filing date
ACUMEN PHARMACEUTICALS INC00509G209CMN1,100,000$11,033,000thousands by filing date
KARYOPHARM THERAPEUTICS INC48576U106COM1,935,609$10,568,000thousands by filing date
ALLAKOS INC01671P100COM1,643,500$10,058,000thousands by filing date
ALPINE IMMUNE SCIENCES INC02083G100COM1,325,000$9,540,000thousands by filing date
CELCUITY INC15102K100COM920,464$9,241,000thousands by filing date
ENANTA PHARMACEUTICALS INC29251M106COM103,494$5,368,000thousands by filing date
KALVISTA PHARMACEUTICALS INC483497103COM312,553$4,535,000thousands by filing date
REZOLUTE INC76200L309COMMON STOCK1,210,000$3,315,000thousands by filing date
ESPERION THERAPEUTICS INC NEW COM29664W105Stock467,468$3,132,000thousands by filing date
IMMUNIC INC4525EP101COM893,013$2,822,000thousands by filing date
BCLS ACQUISITION CORPG0904B105CMN250,000$2,505,000thousands by filing date
LARIMAR THERAPEUTICS INC517125100COM750,000$2,400,000thousands by filing date
TERNS PHARMACEUTICALS INC COM880881107Stock205,870$1,213,000thousands by filing date

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001831942-22-000007this filing2022-11-14acceptance time not in the bulk data set